Trending...
- Graphis to Publish Kit Hinrichs' New Book: Narrative Design
- Marsha Gay Reynolds Shares Insights on In-Home Care Post-Pandemic
- ShopCHARLI.com Launches Online Store With a Hot New Spring Collection that Doesn't Miss
SAN JOSE, Calif. - iSportsWire -- CPC Scientific Inc., a leading global peptide CRDMO (Contract Research, Development, and Manufacturing Organization) has invested in a new peptide API (Active Pharmaceutical Ingredient) manufacturing site, bringing many new jobs to Rocklin, California. The 41,000 sq ft facility located at 3880 Atherton Rd, Rocklin, CA 95765 will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity and will diversify CPC Scientific's supply chain.
"CPC Scientific is entering an exciting period of growth and innovation for peptide and oligonucleotide therapeutic development and manufacturing, and we will continue to provide therapeutic APIs to pharmaceutical and biotech companies around the world. We are very pleased to partner with the City of Rocklin, California to bring manufacturing and Life-Science jobs to local American workers," said Shawn Lee, Ph.D., CEO.
Expanding CPC Scientific's manufacturing footprint in North America enables them to continue to produce innovative peptide products while providing additional capacity to specialty peptide APIs more rapidly.
More on iSports Wire
Peptide-based therapeutic candidates have been the fastest growing sector among all the chemical synthesized NCEs (New Chemical Entities) for new drug development in recent years. For over two decades, CPC Scientific has been a reliable partner for its clients all over the world including multinational pharmaceutical companies, biotech companies, and academic institutions by providing value-added one-stop-shop development and manufacturing services to support their clinical trials. CPC Scientific has been successfully supplying commercialized APIs to their clients in the U.S., Europe, Australia, Japan, and China for their peptide-based drugs and medical devices. By expanding their GMP manufacturing footprint, the CRDMO will enable their clients and partners to have multiple geographic options to ensure a secure API supply chain.
"We have helped many of our clients to bring an innovative drug into the market from a concept. With the new Rocklin site, we believe we will be able to contribute more especially to the Northern American market and we will continue making our efforts with our decades of peptide synthesis expertise to help our clients to save lives and improve human health worldwide," said Shawn Lee, Ph.D.
More on iSports Wire
The new Rocklin CGMP facility is scheduled to be online and fully operational by 2023. With manufacturing operations in Hangzhou (CN) and Rocklin, CA (US), these facilities will enable CPC Scientific to help meet the growing worldwide demand for peptide-based therapeutics and diagnostics.
About CPC Scientific.
Founded in 2001, CPC Scientific is a globally recognized and leading CRDMO specializing in synthetic peptide production, which is also expanding its footprint in synthetic oligonucleotides. The company works directly with leaders in the biotechnology and pharmaceutical industries to help bring life-changing therapeutics and diagnostics to market. CPC Scientific has the capability of serving customers from early drug discovery stages through clinical trials to commercial manufacturing and is proudly supplying commercial APIs to our partners all over the world. Dozens of isolated process and purification suites for peptide manufacturing enable simultaneous multi-Kg batch size projects. With an emphasis on technology, innovation, and experience, we are proud to have facilities inspected by many government agencies including U.S. Food and Drug Administration (FDA).
"CPC Scientific is entering an exciting period of growth and innovation for peptide and oligonucleotide therapeutic development and manufacturing, and we will continue to provide therapeutic APIs to pharmaceutical and biotech companies around the world. We are very pleased to partner with the City of Rocklin, California to bring manufacturing and Life-Science jobs to local American workers," said Shawn Lee, Ph.D., CEO.
Expanding CPC Scientific's manufacturing footprint in North America enables them to continue to produce innovative peptide products while providing additional capacity to specialty peptide APIs more rapidly.
More on iSports Wire
- Eve Wellness, a SF Breast Ultrasound Screening Clinic supports the recent FDA updates to the guidelines to inform women about breast density
- Expert tip: Private Jet Engine Maintenance Program - Pros and Cons for Preowned Jet Buyers
- Gaming and entertainment company Spinrack Corporation, appoints Jesse Norton as Chief Marketing Officer
- .Store Domains launches Elevate.store – a free-to-use platform for online sellers with deals on business tools
- JKS Financial Partners with Pitt Men's Basketball to Support United Way of Southwestern Pennsylvania
Peptide-based therapeutic candidates have been the fastest growing sector among all the chemical synthesized NCEs (New Chemical Entities) for new drug development in recent years. For over two decades, CPC Scientific has been a reliable partner for its clients all over the world including multinational pharmaceutical companies, biotech companies, and academic institutions by providing value-added one-stop-shop development and manufacturing services to support their clinical trials. CPC Scientific has been successfully supplying commercialized APIs to their clients in the U.S., Europe, Australia, Japan, and China for their peptide-based drugs and medical devices. By expanding their GMP manufacturing footprint, the CRDMO will enable their clients and partners to have multiple geographic options to ensure a secure API supply chain.
"We have helped many of our clients to bring an innovative drug into the market from a concept. With the new Rocklin site, we believe we will be able to contribute more especially to the Northern American market and we will continue making our efforts with our decades of peptide synthesis expertise to help our clients to save lives and improve human health worldwide," said Shawn Lee, Ph.D.
More on iSports Wire
- GP GLOBAL GROUP Secures $18M Sale of Shoppes at 41st Street Retail Plaza in Doral, Florida, with $11.5M CMBS Loan Assumption
- HLN's Immunization Calculation Engine (ICE) is continually updated to support new COVID-19 recommendations
- Subsneeded Signs Up 'First' Free Agent CM Soccer Player in Dearborn Michigan
- Rewilding Ireland with Lord Dunsany and IrishTrees
- The Tokyo Rebels Announces the Release of Their Groundbreaking Whitepaper
The new Rocklin CGMP facility is scheduled to be online and fully operational by 2023. With manufacturing operations in Hangzhou (CN) and Rocklin, CA (US), these facilities will enable CPC Scientific to help meet the growing worldwide demand for peptide-based therapeutics and diagnostics.
About CPC Scientific.
Founded in 2001, CPC Scientific is a globally recognized and leading CRDMO specializing in synthetic peptide production, which is also expanding its footprint in synthetic oligonucleotides. The company works directly with leaders in the biotechnology and pharmaceutical industries to help bring life-changing therapeutics and diagnostics to market. CPC Scientific has the capability of serving customers from early drug discovery stages through clinical trials to commercial manufacturing and is proudly supplying commercial APIs to our partners all over the world. Dozens of isolated process and purification suites for peptide manufacturing enable simultaneous multi-Kg batch size projects. With an emphasis on technology, innovation, and experience, we are proud to have facilities inspected by many government agencies including U.S. Food and Drug Administration (FDA).
Source: CPC Scientific Inc.
0 Comments
Latest on iSports Wire
- Introducing Music360, the New Social Music Streaming App
- Marsha Gay Reynolds Shares Insights on In-Home Care Post-Pandemic
- IOTech announces a new release of Edge Xrt, its high performance data connectivity solution for industrial systems
- Homestead Training Center To Sponsor the 2023 IDPA World Championship
- ANIMAL RIGHTS PROTEST at The Animal Foundation of Las Vegas
- Graphis to Publish Kit Hinrichs' New Book: Narrative Design
- The expansion continues at Right Cars Global Rentals as it officially announces its opening in the Dominican Republic
- Subsneeded Signs Up 'First' Men's Adult Softball Free Agent in Westminster, Colorado
- Amy Sport Renews Partnership With Southern California PGA
- King Me: Loving and Leading in a Wounding World Releases March 15, 2023
- The Official Drink Of Juneteenth Atlanta 2023
- DCA Virtual: Two Decades Since the SBA Has Been Reauthorized – Is This the Year?
- Final X, Beat the Streets' 2023 Annual Benefit, set for June 10 at Prudential Center
- Universal Sequencing Technology Corporation Launches High-Throughput Solution For Microbial WGS Library Preparation
- Kobie Named a Leader in Latest Loyalty Technology Report by Independent Research Firm
- Cat and Kitten Adoption, Saturday, April 29th Douglas Infiniti 430 Morris Ave. Summit, NJ
- Today is GENIUS Day celebrate with Dr. Tracey Bond, Iconic Creator of the #DO7E Transformational GENIUS Experientia & Coachery™ at DrTraceyBond.com
- Omnitronics introduces omnicore Express: The Feature-Rich Radio Dispatch Console for Small to Medium Organizations
- Alpha Gold Fund - Twelve Month Performance Market Update
- Michael Ahrnsbrak, PGA, Joins Up to Par Management as Director of Business Development